Abstract

The present review briefly summarizes the highlights of the recent advances in Mycobacterium leprae specific tests for early diagnosis of leprosy. In addition to establishing the diagnosis ofclinical cases of leprosy, these tests have also been used to detect subclinical infections in endemic population. Several attempts have been made from 1980 onward for standardization of specific diagnostic assays for early detection of leprosy. Brief account about the development and use ofthese assays has been described in this review article.

• 1.   World Health Organization. Global leprosy update, 2016: accelerating reduction of disease burden. Wkly Epidemiol Rec. 2017 Sep 1;92(35):501–20.
• 2.   National Leprosy Eradication Programme. NLEP annual report 2015-2016 [Internet]. New Delhi: Central Leprosy Division, Directorate General of Health Services; [cited 2017 Sep 12].
• 3.   National Leprosy Eradication Programme. NLEP annual report 2016-2017 [Internet]. New Delhi: Central Leprosy Division, Directorate General of Health Services; [cited 2018 Feb 22].
• 4.   Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119–28.
• 5.   Ridley DS, Ridley MJ. Classification of nerves is modified by the delayed recognition of M. leprae. Int J Lepr Other Mycobact Dis. 1986;54(4):596–600.
• 6.   Forno C, Hausermann P, Hatz C, Itin P, Blum J. The difficulty in diagnosis and treatment of leprosy. J Travel Med. 2010;17(4):281–3.
• 7.   Gupte MD, Anantharaman DS, Nagaraju B, Kannan S, Vallishayee RS. Experiences with Mycobacterium leprae soluble antigens in a leprosy endemic population. Lepr Rev. 1990;61(2):132–44.
• 8.   Sengupta U. Experience and lessons from the use of lepromin and Mycobacterium leprae-specific serology. Lepr Rev. 2000;71 Suppl:S63–6.
• 9.   Brennan PJ, Barrow WW. Evidence for species-specific lipid antigens in Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1980;48(4):382–7.
• 10.   Cho SN, Yanagihara DL, Hunter SW, Gelber RH, Brennan PJ. Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun. 1983;41(3):1077–83.
• 11.   Young DB, Buchanan TM. A serological test for leprosy with a glycolipid specific for Mycobacterium leprae. Science. 1983;221(4615):1057–9.
• 12.   Brett SJ, Draper P, Payne SN, Rees RJ. Serological activity of a characteristic phenolic glycolipid from Mycobacterium leprae in sera from patients with leprosy and tuberculosis. Clin Exp Immunol. 1983;52(2):271–9.
• 13.   Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. J Biol Chem. 1982;257(24):15072–8.
• 14.   Brett SJ, Payne SN, Draper P, Gigg R. Analysis of the major antigenic determinants of the characteristic phenolic glycolipid from Mycobacterium leprae. Clin Exp Immunol. 1984;56(1):89–96.
• 15.   Fujiwara T, Hunter SW, Cho SN, Aspinall GO, Brennan PJ. Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun. 1984;43(1):245–52.
• 16.   Chatterjee D, Cho SN, Brennan PJ, Aspinall GO. Chemical synthesis and seroreactivity of O-(3,6-di-O-methyl-beta-D-glucopyranosyl)-(1----4)-O-(2,3-di-O-methyl-alpha-L-rhamnopyranosyl)-(1----9)-oxynonanoyl-bovine serum albumin--the leprosy-specific, natural disaccharide-octyl-neoglycoprotein. Carbohydr Res. 1986;156:39–56.
• 17.   Fujiwara T, Aspinall GO, Hunter SW, Brennan PJ. Chemical synthesis of the trisaccharide unit of the species-specific phenolic glycolipid from Mycobacterium leprae. Carbohydr Res. 1987;163(1):41–52.
• 18.   Gigg J, Gigg R, Payne S, Conant R. The allyl group for protection in carbohydrate chemistry: synthesis of propyl O-(3,6-di-O-methyl-beta-D-glucopyranosyl)-(1-4)-O-(2,3-di-O-methyl-alpha-L-rhamnopyranosyl)-(1-2)-3-O-methyl-alpha-L-rhamnopyranoside: the oligosaccharide portion of the major serologically active glycolipid from Mycobacterium leprae. Chem Phys Lipids. 1985;38(3-4):299–307.
• 19.   Schwerer B, Meeker HC, Sersen G, Levis WR. IgM antibodies against phenolic glycolipid I from Mycobacterium leprae in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Acta Leprol. 1984;2(4):394–402.
• 20.   Bach MA, Wallach D, Flageul B, Hoffenbach A, Cottenot F. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Int J Lepr Other Mycobact Dis. 1986;54(2):256–67.
• 21.   Sinha S, McEntegart A, Girdhar BK, Bhatia AS, Sengupta U. Appraisal of two Mycobacterium leprae-specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Int J Lepr Other Mycobact Dis. 1989;57(1):24–32.
• 22.   Roche PW, Britton WJ, Failbus SS, Williams D, Pradhan HM, Theuvenet WJ. Operational value of serological measurements in multibacillary leprosy patients: clinical and bacteriological correlates of antibody responses. Int J Lepr Other Mycobact Dis. 1990;58(3):480–90.
• 23.   Lyons NF, Shannon EJ, Ellis BP, Naafs B. Association of IgG and IgM antibodies to phenolic glycolipid-1 antigen of Mycobacterium leprae with disease parameters in multibacillary leprosy patients. Lepr Rev. 1988;59(1):45–52.
• 24.   Bührer-Sékula S, Cunha MG, Ferreira WA, Klatser PR. The use of whole blood in a dipstick assay for detection of antibodies to Mycobacterium leprae: a field evaluation. FEMS Immunol Med Microbiol. 1998;21(3):197–201.
• 25.   Bührer-Sékula S, Cunha MG, Foss NT, Oskam L, Faber WR, Klatser PR. Dipstick assay to identify leprosy patients who have an increased risk of relapse. Trop Med Int Health. 2001;6(4):317–23.
• 26.   Izumi S, Fujiwara T, Ikeda M, Nishimura Y, Sugiyama K, Kawatsu K. Novel gelatin particle agglutination test for serodiagnosis of leprosy in the field. J Clin Microbiol. 1990;28(3):525–9.
• 27.   Bührer-Sékula S, Smits HL, Gussenhoven GC, van Leeuwen J, Amador S, Fujiwara T, et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol. 2003;41(5):1991–5.
• 28.   Zenha EM, Ferreira MA, Foss NT. Use of anti-PGL-1 antibodies to monitor therapy regimens in leprosy patients. Braz J Med Biol Res. 2009;42(10):968–72.
• 29.   Bach MA, Wallach D, Flageul B, Hoffenbach A, Cottenot F. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Int J Lepr Other Mycobact Dis. 1986;54(2):256–67. [Duplicate of Reference 20]
• 30.   Roche PW, Britton WJ, Failbus SS, Neupane KD, Theuvenet WJ. Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr Other Mycobact Dis. 1993;61(1):35–43.

Data Sharing Statement

Funding